Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308272 | 0.88 | EHMT2 (0.49) | EHMT2MEN1MAPTKMT2A | |
| SCHEMBL830075 | 0.88 | EHMT2 (0.52) | EHMT2MMP1MMP3MMP9MEN1 | |
| SCHEMBL10064199 | 0.85 | EHMT2 (0.47) | EHMT2MMP1MMP3MMP9 | |
| SCHEMBL828397 | 0.83 | MMP1 (0.56) | EHMT2MMP1MMP3MMP9 | |
| SCHEMBL10064039 | 0.79 | EHMT2 (0.44) | EHMT2MMP1MMP3MMP9MEN1 | |
| SCHEMBL830079 | 0.77 | HDAC3 (0.47) | EHMT2MMP1MMP3MMP9MEN1 | |
| SCHEMBL829775 | 0.77 | EHMT2 (0.54) | EHMT2MEN1KMT2A | |
| SCHEMBL830001 | 0.77 | EHMT2 (0.50) | EHMT2MMP1MMP3MMP9MEN1 | |
| SCHEMBL23454666 | 0.76 | MEN1 (0.58) | EHMT2MMP1MMP3MMP9MEN1 | |
| SCHEMBL26089994 | 0.76 | MEN1 (0.58) | EHMT2MMP1MMP3MMP9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178783-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8143445-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178783-A1 | HDAC INHIBITORS | HDAC3, HDAC4, HDAC7 | EHMT2 88/4885MMP1 1804/4885MMP3 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.